MAIA Biotechnology Announces Closing of $30 Million Underwritten Public Offering of Common Stock

Core Viewpoint - MAIA Biotechnology, Inc. has successfully closed a public offering of 20 million shares at $1.50 per share, raising a total of $30 million for clinical trials and general corporate purposes [1][2]. Group 1: Offering Details - The public offering consisted of 20,000,000 shares priced at $1.50 each, resulting in gross proceeds of $30 million before expenses [1]. - The underwriters have a 30-day option to purchase an additional 3,000,000 shares at the same price to cover any overallotments [1]. - The offering was structured as a common stock-only investment with no warrant coverage, led by healthcare-dedicated investors [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for conducting clinical trials, working capital, and general corporate purposes [2]. Group 3: Company Background - MAIA Biotechnology is focused on developing targeted immunotherapies for cancer, with its lead program being ateganosine (THIO), aimed at treating NSCLC patients with telomerase-positive cancer cells [7].